BostonGene to Present Research with Leading Cancer Centers at Society for Immunotherapy of Cancer’s 2023 Annual Meeting

Four Studies Highlight the Powerful Potential of BostonGene’s Molecular and Immune Profiling and Advanced Transcriptomic Analysis to Transform Precision Medicine for Cancer Patients

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA. BostonGene will also exhibit at booth 639.

BostonGene session details are below:

Abstract: 143
Title: Correlating RNA-Seq Detection and IHC Staining of Potential ADC Targets: HER3, TROP2, Nectin4 and aFLR
Date and time: Friday, November 3 | 12:00 PM – 1:30 PM and 5:10 PM – 6:40 PM
Location: Exhibit Hall B
Presenter: Alexander Bagaev, PhD, BostonGene

This study showed that the IHC results of five promising ADC targets (HER3, HER2, TROP2, Nectin4, and aFLR) correlated with their RNA sequencing (RNA-seq) gene expression values, highlighting the potential use of RNA-seq to detect ADC targets.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center

Abstract: 555
Title: Challenges in Predicting ICI Response in HPV+ HNSCC: Insights into the Tumor Microenvironment
Date and time: Friday, November 3 | 12:00 PM – 1:30 PM and 5:10 PM – 6:40 PM
Location: Exhibit Hall B
Presenter: Anastasia Nikitina, PhD, BostonGene

Transcriptomic analysis of human papillomavirus (HPV)+ head and neck squamous cell carcinomas (HNSCCs) revealed a disparity in underlying mechanisms of ICI response, particularly related to the tumor microenvironment (TME), between HPV- and HPV+ HNSCC patients. This study underscores the importance of considering a patient’s HPV status when assessing mechanisms associated with ICI response in HNSCC.

Research conducted in collaboration with Thomas Jefferson University

Abstract: 222-K
Title: Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)
Date and time: Saturday, November 4 | 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM
Location: Exhibit Hall B
Presenter: Michael Goldberg, PhD, BostonGene

In this study, immunoprofiling of peripheral blood cells in combination with RNA-seq of tumor tissues identified novel predictors of anti-PD-1 response in HNSCC, suggesting the utility of this integrated approach as a tool to develop biologic predictors of ICI response that can lead to more effective personalized treatment options for cancer patients.

Research conducted in collaboration with Thomas Jefferson University

Abstract: 532
Title: A Cross-Cohort Examination of Factors Impacting Immunotherapy Survival in Non-Small Cell Lung Cancer (NSCLC)
Date and time: Saturday, November 4 | 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM
Location: Exhibit Hall B
Presenter: Nikita Kotlov, BostonGene

BostonGene’s transcriptome-based TME classification approach and proprietary cell deconvolution tool Kassandra were used to identify the TME subtypes and characterize the TME cell types of NSCLC patients treated with ICIs. The results showed that the TME subtypes and CD8+ T cell infiltration were associated with overall and progression-free survival, indicating their potential as predictive biomarkers for immunotherapy response.

Research conducted in collaboration with St Luke’s Cancer Institute

To learn more or to schedule a meeting with BostonGene during SITC, please contact Maria Proia at [e-mail].

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.